Asia-Pacific Liquid Biopsy Market, By Product (Instruments, Consumables & Accessories, Services & Software), Biomaker Type (Circulating Tumor Cells (CTCS), Circulating Cell-Free DNA (CFDNA), Cell-free RNA, Extracellular Vesicles, Exosomes, and Others), Sample Type (Blood Sample-Based, Urine Sample-Based, Saliva & Other Tissue Fluid Sample-Based, and Others), Analytical Type (Molecular, Proteomics, and Histology/Imaging), Application Type (Cancer Applications and Non-Cancer Applications), Clinical Application (Routine Screening, Patient Work-Up, Therapy Selection, Treatment Monitoring, Recurrence Monitoring, and Others), Technology (Multi-Gene Parallel Analysis, and Single-Gene Analysis), End User (Hospitals, Reference Laboratories, Diagnostic Centers, Research Centers & Academic Institutes, and Others), Distribution Channel (Direct Tender, Third Party Distributor, and Others) - Industry Trends and Forecast to 2030.
Asia-Pacific Liquid Biopsy Market Analysis and Insights
The increasing awareness of advanced diagnostic technology Asia-Pacific has enhanced the demand for the market. The rising healthcare expenditure for better health services also contributes to the market's growth. The major market players focus on various service launches and approvals during this crucial period. In addition, the increase in improved advancement of processes and techniques also contributes to the rising demand for liquid biopsy.
The Asia-Pacific liquid biopsy market is expected to grow in the forecast year due to the rise in market players and the availability of advanced services. Along with this, manufacturers are engaged in the developmental activity for launching novel services in the market. The increasing development in the field of advanced healthcare techniques is further boosting market growth.
However, difficulties such as the lack of standardized protocols and the lack of skilled professionals might hamper the growth of the Asia-Pacific liquid biopsy market in the forecast period.
Data Bridge Market Research analyzes that the Asia-Pacific liquid biopsy market is expected to grow at a CAGR of 13.4% during the forecast period of 2023 to 2030.
|
Report Metric |
Details |
|
Forecast Period |
2023 to 2030 |
|
Base Year |
2022 |
|
Historic Years |
2021 (Customizable to 2015- 2020) |
|
Quantitative Units |
Revenue in Million, Volumes in Units, Pricing in USD |
|
Segments Covered |
Producto (instrumentos, consumibles y accesorios, servicios y software), tipo de biofabricante (células tumorales circulantes [CTCS], ADN libre de células circulantes [CFDNA], ARN libre de células, vesículas extracelulares, exosomas y otros), tipo de muestra (basada en muestras de sangre, muestras de orina, muestras de saliva y otros fluidos tisulares y otros), tipo analítico (molecular, proteómica e histología/imágenes), tipo de aplicación (aplicaciones oncológicas y aplicaciones no oncológicas), aplicación clínica (examen de rutina, evaluación del paciente, selección de terapia, monitoreo del tratamiento, monitoreo de recurrencia y otros), tecnología (análisis paralelo de múltiples genes y análisis de un solo gen), usuario final (hospitales, laboratorios de referencia, centros de diagnóstico, centros de investigación e institutos académicos y otros), canal de distribución (licitación directa, distribuidor externo y otros) |
|
Países cubiertos |
Japón, China, Australia, India, Corea del Sur, Singapur, Indonesia, Tailandia, Malasia, Filipinas y resto de Asia-Pacífico |
|
Actores del mercado cubiertos |
F. Hoffmann-La Roche Ltd, Guardant Health, Thermo Fisher Scientific Inc., Exact Sciences Corporation (salud genómica), QIAGEN, Labcorp, Johnson & Johnson Services, Inc., Illumina Inc, NeoGenomics Laboratories, Bio-Rad Laboratories, Inc., Natera, Inc., CARDIFF ONCOLOGY, INC., Sysmex Inostics Inc. y BIOCEPT, INC., entre otros. |
Definición de mercado
Una biopsia líquida es una prueba médica que implica el análisis de diversas biomoléculas, como ADN, ARN, proteínas y otras sustancias en la sangre u otros fluidos corporales de un paciente, para diagnosticar y controlar diversas afecciones médicas, incluido el cáncer. A diferencia de las biopsias tradicionales que implican la extracción de muestras de tejido del cuerpo, una biopsia líquida no es invasiva y puede proporcionar información diagnóstica importante sin la necesidad de cirugía u otros procedimientos invasivos. Las biopsias líquidas aún se encuentran en las primeras etapas de desarrollo, pero son prometedoras para mejorar la detección y el tratamiento del cáncer y otras enfermedades.
Dinámica del mercado de biopsia líquida en Asia-Pacífico
Esta sección trata sobre la comprensión de los factores impulsores del mercado, las ventajas, las oportunidades, las limitaciones y los desafíos. Todo esto se analiza en detalle a continuación.
Conductores
- Creciente demanda de técnicas de biopsia líquida no invasivas
Las biopsias líquidas consisten en aislar entidades derivadas de tumores como células tumorales circulantes, ADN tumoral circulante y vesículas extracelulares tumorales, entre otras, presentes en los fluidos corporales de pacientes con cáncer, seguido de un análisis de los datos genómicos y proteómicos contenidos en ellas. Los métodos para el aislamiento y análisis de biopsias líquidas han evolucionado rápidamente en los últimos años, como se describe en la revisión, proporcionando así mayores detalles sobre las características del tumor como mutaciones, estadificación del tumor, progresión del tumor, heterogeneidad y evolución genética y clonal, entre otras. Las biopsias líquidas de pacientes con cáncer han abierto nuevas vías en la detección y el seguimiento continuo, el tratamiento basado en la medicina de precisión y la detección de marcadores de resistencia terapéutica. Los diagnósticos no invasivos del cáncer ofrecen un enfoque más seguro y amigable para el paciente, lo que resulta en una creciente demanda de estos métodos.
- Avances en la medicina de precisión gracias a la biopsia líquida
La oncología médica de precisión en el tratamiento clínico del cáncer se puede lograr a través de la plataforma de diagnóstico denominada "biopsia líquida" (LB). La LB fue reconocida como un poderoso enfoque en tiempo real para el monitoreo molecular de esta enfermedad oncológica dinámica. Este método utiliza la detección de biomarcadores en sangre con fines de pronóstico y predicción por medios no invasivos, lo que en un futuro cercano representará un cambio en el paradigma de la comprensión de la biología molecular y la heterogeneidad de los tumores. Los avances en la medicina de precisión, impulsados por el uso de técnicas de biopsia líquida, han contribuido significativamente a la creciente demanda de diagnósticos no invasivos del cáncer. Las técnicas de biopsia líquida, como el análisis del ADN tumoral circulante (ctDNA), las células tumorales circulantes (CTC) o los exosomas en la sangre u otros fluidos corporales, brindan información valiosa sobre la composición genética de los tumores, lo que permite enfoques de medicina de precisión en el tratamiento del cáncer.
Oportunidad
- Integración de inteligencia artificial (IA) y aprendizaje automático
Los métodos basados en biopsia líquida ofrecen muchas nuevas oportunidades para medir biomarcadores moleculares con el fin de diagnosticar, pronosticar y monitorear enfermedades. La inteligencia artificial (IA), como el aprendizaje automático, y su capacidad para identificar características de estados patológicos específicos en datos multiplexados serán fundamentales para aprovechar la nueva información molecular que pueden extraer los diagnósticos basados en microchips.
Por lo tanto, se espera que la integración de la IA y el aprendizaje automático actúe como una oportunidad para el crecimiento del mercado.
- Aumentar los reembolsos y el apoyo gubernamental para la biopsia líquida
La adopción de la biopsia líquida ha sido influenciada significativamente por el respaldo gubernamental. Los gobiernos de todo el mundo han promulgado leyes para fomentar la adopción de la biopsia líquida porque entienden que puede mejorar la atención al paciente, reducir los costos de la atención médica y hacer avanzar la medicina de precisión. La incorporación de la biopsia líquida en los programas nacionales de detección del cáncer o en las recomendaciones de tratamiento es solo un ejemplo de cómo se podría hacer esto. Otros ejemplos incluyen la financiación de la investigación y el desarrollo de tecnologías de biopsia líquida y el respaldo de ensayos y estudios clínicos para producir evidencia sobre su eficacia terapéutica. Esta asistencia gubernamental ha ayudado a impulsar el conocimiento, la adopción y la cobertura de reembolso de la prueba de biopsia líquida.
Por lo tanto, se espera que el aumento de los reembolsos y el apoyo gubernamental a la biopsia líquida actúen como una oportunidad para el crecimiento del mercado.
Restricción/Desafío
- Alto costo de las pruebas de biopsia líquida
La biopsia líquida se ve seriamente limitada por su elevado coste. Si bien las pruebas de biopsia líquida son prometedoras para la detección y el seguimiento no invasivos de enfermedades, incluido el cáncer, existen obstáculos relacionados con el coste que pueden impedir su uso generalizado.
La necesidad de herramientas y tecnologías especializadas es uno de los mayores obstáculos económicos. Con frecuencia, se necesitan herramientas costosas, como máquinas de PCR digital, plataformas de NGS y sistemas de procesamiento automatizado de muestras, para los estudios de biopsia líquida. A los centros de salud más pequeños con presupuestos más ajustados puede resultarles difícil afrontar la inversión inicial y los costos de mantenimiento continuos relacionados con estas tecnologías, lo que limita su capacidad para proporcionar pruebas de biopsia líquida a los pacientes.
Por lo tanto, se espera que el alto costo de las pruebas de biopsia líquida restrinja el crecimiento del mercado.
- Falta de profesionales capacitados para realizar biopsia líquida
La demanda de pruebas de biopsia líquida está aumentando debido a su posible utilidad clínica en la detección y el seguimiento del cáncer y la toma de decisiones personalizadas sobre el tratamiento. Sin embargo, puede haber recursos limitados, incluidos personal, equipos y financiación, para respaldar la implementación de programas de biopsia líquida en instituciones de atención médica. Esto puede dar lugar a una escasez de profesionales capacitados que puedan realizar pruebas de biopsia líquida, especialmente en regiones o entornos de atención médica con recursos limitados.
Por lo tanto, se espera que la falta de profesionales capacitados que realicen biopsias líquidas suponga un desafío para el crecimiento del mercado.
Desarrollo reciente
- En enero de 2022, Exact Sciences Corporation anunció la adquisición de Prevention Genetics, un laboratorio de pruebas genéticas, para complementar su cartera de diagnóstico avanzado del cáncer y respaldar su ingreso a las pruebas de cáncer hereditario (HCT).
Alcance del mercado de biopsia líquida en Asia y el Pacífico
El mercado de biopsia líquida de Asia-Pacífico se clasifica en nueve segmentos notables que son producto, tipo de biofabricante, tipo de muestra, tipo analítico, tipo de aplicación, aplicación clínica, tecnología, usuario final y canal de distribución. El crecimiento entre estos segmentos lo ayudará a analizar los segmentos de crecimiento del mercado en las industrias y brindará a los usuarios una valiosa descripción general del mercado y conocimientos del mercado para ayudarlos a tomar decisiones estratégicas para identificar las principales aplicaciones del mercado.
Producto
- Instrumentos
- Consumibles y accesorios
- Servicios y software
Según el producto, el mercado está segmentado en instrumentos, consumibles y accesorios, servicios y software.
Tipo de biofabricante
- Células tumorales circulantes (CTCS)
- ADN libre circulante (CFDNA)
- ARN libre de células
- Exosomas
- Vesículas extracelulares
- Otros
Según el tipo de biofabricante, el mercado está segmentado en células tumorales circulantes (CTCS), ADN libre de células circulantes (CFDNA), ARN libre de células, vesículas extracelulares, exosomas y otros.
Tipo de muestra
- Basado en muestras de sangre
- Basado en muestra de orina
- Muestras de saliva y otros fluidos tisulares
- Otros
Según el tipo de muestra, el mercado se segmenta en muestras de sangre, muestras de orina, muestras de saliva y otros fluidos tisulares, entre otros.
Tipo Analítico
- Molecular
- Proteómica
- Histología/Imagenología
Sobre la base del tipo de análisis, el mercado está segmentado en molecular, proteómica e histología/imagen.
Tipo de aplicación
- Aplicaciones contra el cáncer
- Aplicaciones no relacionadas con el cáncer
Según el tipo de aplicación, el mercado está segmentado en aplicaciones oncológicas y aplicaciones no oncológicas.
Aplicación clínica
- Examen de rutina
- Selección de terapia
- Seguimiento del tratamiento
- Monitoreo de recurrencia
- Evaluación del paciente
- Otros
Sobre la base de la aplicación clínica, el mercado está segmentado en detección de rutina, evaluación del paciente, selección de terapia, seguimiento del tratamiento, seguimiento de la recurrencia y otros.
Tecnología
- Análisis paralelo de múltiples genes
- Análisis de un solo gen
Sobre la base de la tecnología, el mercado está segmentado en análisis paralelo de múltiples genes y análisis de un solo gen.
Usuario final
- Hospitales
- Laboratorios de referencia
- Centros de diagnóstico
- Centros de investigación e institutos académicos
- Otros
Según el usuario final, el mercado se segmenta en hospitales, laboratorios de referencia, centros de diagnóstico, centros de investigación e institutos académicos, y otros.
Canales de distribución
- Licitación directa
- Distribuidor externo
- Otros
Sobre la base del canal de distribución, el mercado se segmenta en licitación directa, distribuidor externo y otros.
Análisis y perspectivas regionales del mercado de biopsia líquida en Asia y el Pacífico
Se analiza el mercado de biopsia líquida de Asia-Pacífico y se proporcionan información y tendencias sobre el tamaño del mercado según el producto, el tipo de biofabricante, el tipo de muestra, el tipo analítico, el tipo de aplicación, la aplicación clínica, la tecnología, el usuario final y el canal de distribución.
Los países cubiertos en este informe de mercado son Japón, China, Australia, India, Corea del Sur, Singapur, Indonesia, Tailandia, Malasia, Filipinas y el resto de Asia-Pacífico.
In 2023, Japan is expected to dominate the Asia-Pacific liquid biopsy market due to technological advancements in liquid biopsy platforms in the country.
The country section of the report also provides individual market-impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as downstream and upstream value chain analysis, technical trends, Porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands and the impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data
Competitive Landscape and Asia-Pacific Liquid Biopsy Market Share Analysis
The Asia-Pacific liquid biopsy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Asia-Pacific presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, brand analysis, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to the Asia-Pacific liquid biopsy market.
Some of the major players in the Asia-Pacific liquid biopsy market are F. Hoffmann-La Roche Ltd, Guardant Health, Thermo Fisher Scientific Inc., Exact Sciences Corporation (Genomic health), QIAGEN, Labcorp, Johnson & Johnson Services, Inc., Illumina Inc, NeoGenomics Laboratories, Bio-Rad Laboratories, Inc., Natera, Inc., CARDIFF ONCOLOGY, INC., Sysmex Inostics Inc., and BIOCEPT, INC. among others.
SKU-
Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo
- Panel de análisis de datos interactivo
- Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
- Acceso de analista de investigación para personalización y consultas
- Análisis de la competencia con panel interactivo
- Últimas noticias, actualizaciones y análisis de tendencias
- Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Tabla de contenido
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE ASIA-PACIFIC LIQUID BIOPSY MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET TESTING TYPE COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
5 INDUSTRY INSIGHTS:
6 ASIA-PACIFIC LIQUID BIOPSY MARKET, REGULATION
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 GROWING DEMAND FOR NON-INVASIVE LIQUID BIOPSY TECHNIQUE
7.1.2 ADVANCEMENTS IN PRECISION MEDICINE DUE TO LIQUID BIOPSY
7.1.3 INCREASING CANCER PREVALENCE AND AWARENESS
7.1.4 TECHNOLOGICAL ADVANCEMENTS IN LIQUID BIOPSY PLATFORMS
7.2 RESTRAINTS
7.2.1 HIGH COST OF LIQUID BIOPSY TESTS
7.2.2 LACK OF STANDARDIZED GUIDELINES
7.3 OPPORTUNITIES
7.3.1 INTEGRATION OF ARTIFICIAL INTELLIGENCE (AI) AND MACHINE LEARNING
7.3.2 INCREASING REIMBURSEMENTS AND GOVERNMENT SUPPORT FOR LIQUID BIOPSY
7.3.3 INCREASING R&D ACTIVITIES BY INSTITUTES
7.4 CHALLENGES
7.4.1 LACK OF SKILLED PROFESSIONALS PERFORMING LIQUID BIOPSY
7.4.2 INCREASED DEPENDENCY ON OTHER BIOPSIES
8 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY PRODUCT
8.1 OVERVIEW
8.2 CONSUMABLES & ACCESSORIES
8.2.1 TEST KITS
8.2.1.1 TOTAL NUCLEIC ACID ISOLATION KIT
8.2.1.2 DNA ISOLATION KIT
8.2.1.3 OTHERS
8.2.2 COLLECTION TUBES
8.2.2.1 50 PIECES
8.2.2.2 100 PIECES
8.2.3 ASSAYS
8.2.3.1 FLEXIBLE REAGENTS
8.2.3.2 SCALABLE REAGENTS
8.2.3.3 OTHERS
8.2.4 CONTROL KIT
8.2.5 OTHERS
8.3 INSTRUMENTS
8.3.1 ANALYZERS
8.3.2 SYSTEMS
8.3.3 OTHERS
8.4 SERVICES & SOFTWARE
8.4.1 NGS ANALYSIS AND REPORTING SOFTWARE
8.4.2 DPCR ANALYSIS SOFTWARE
8.4.3 CASTPCR ANALYSIS SOFTWARE
8.4.4 OTHERS
9 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY BIOMAKER TYPE
9.1 OVERVIEW
9.2 CIRCULATING TUMOR CELLS (CTCS)
9.3 CIRCULATING CELL-FREE DNA (CFDNA)
9.4 CELL-FREE RNA
9.5 EXOSOMES
9.6 EXTRACELLULAR VESICLES
9.7 OTHERS
10 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY SAMPLE TYPE
10.1 OVERVIEW
10.2 BLOOD SAMPLE-BASED
10.3 URINE SAMPLE-BASED
10.4 SALIVA & OTHER TISSUE FLUIDS SAMPLE-BASED
10.5 OTHERS
11 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE
11.1 OVERVIEW
11.2 MOLECULAR
11.2.1 NGS
11.2.2 PCR
11.2.3 MICROARRAY
11.2.4 PROTEOMICS
11.2.5 OTHERS
11.3 PROTEOMIC
11.3.1 NGS
11.3.2 PCR
11.3.3 MICROARRAY
11.3.4 PROTEOMICS
11.3.5 OTHERS
11.4 HISTOLOGY/IMAGING
12 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY APPLICATION TYPE
12.1 OVERVIEW
12.2 CANCER APPLICATIONS
12.2.1 LUNG
12.2.2 BREAST
12.2.2.1 EARLY BREAST CANCER
12.2.2.2 ADVANCED BREAST CANCER
12.2.3 COLORECTAL
12.2.4 PROSTRATE
12.2.5 LIVER
12.2.6 OTHERS
12.3 NON-CANCER APPLICATIONS
12.3.1 PRENATAL DIAGNOSIS
12.3.2 PERSONALIZED IMMUNOTHERAPY
12.3.3 OTHERS
13 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION
13.1 OVERVIEW
13.2 ROUTINE SCREENING
13.3 THERAPY SELECTION
13.4 TREATMENT MONITORING
13.4.1 EARLY-STAGE DISEASE
13.4.2 LATE-STAGE/METASTATIC DISEASE
13.5 RECURRENCE MONITORING
13.6 PATIENT WORK-UP
13.7 OTHERS
14 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY TECHNOLOGY
14.1 OVERVIEW
14.2 MULTI-GENE-PARALLEL ANALYSIS
14.3 SINGLE GENE ANALYSIS
15 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY END USER
15.1 OVERVIEW
15.2 HOSPITALS
15.3 REFERENCE LABORATORIES
15.4 DIAGNOSTIC CENTERS
15.5 RESEARCH CENTERS AND ACADEMIC INSTITUTES
15.6 OTHERS
16 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 DIRECT TENDER
16.3 THIRD PARTY DISTRIBUTOR
16.4 OTHERS
17 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY REGION
17.1 ASIA-PACIFIC
17.1.1 JAPAN
17.1.2 CHINA
17.1.3 SOUTH KOREA
17.1.4 INDIA
17.1.5 AUSTRALIA
17.1.6 SINGAPORE
17.1.7 THAILAND
17.1.8 MALAYSIA
17.1.9 INDONESIA
17.1.10 PHILIPPINES
17.1.11 REST OF ASIA-PACIFIC
18 ASIA-PACIFIC LIQUID BIOPSY MARKET, COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
19 COMPANY PROFILE
19.1 F. HOFFMANN-LA ROCHE LTD.
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENTS
19.2 GUARDANT HEALTH
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENTS
19.3 THERMO FISHER SCIENTIFIC INC.
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 COMPANY SHARE ANALYSIS
19.3.4 SWOT ANALYSIS
19.3.5 PRODUCT PORTFOLIO
19.3.6 RECENT DEVELOPMENTS
19.4 EXACT SCIENCE CORPORATION
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 COMPANY SHARE ANALYSIS
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPMENTS
19.5 QIAGEN
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 COMPANY SHARE ANALYSIS
19.5.4 PRODUCT PORTFOLIO
19.5.5 RECENT DEVELOPMENTS
19.6 ANGLE PLC (2022)
19.6.1 COMPANY SNAPSHOT
19.6.2 REVENUE ANALYSIS
19.6.3 PRODUCT PORTFOLIO
19.6.4 RECENT DEVELOPMENT
19.7 BIOCEPT, INC.
19.7.1 COMPANY SNAPSHOT
19.7.2 REVENUE ANALYSIS
19.7.3 PRODUCT PORTFOLIO
19.7.4 RECENT DEVELOPMENT
19.8 BIO-RAD LABORATORIES, INC. (2022)
19.8.1 COMPANY SNAPSHOT
19.8.2 REVENUE ANALYSIS
19.8.3 PRODUCT PORTFOLIO
19.8.4 RECENT DEVELOPMENTS
19.9 EPIC SCIENCES
19.9.1 COMPANY SNAPSHOT
19.9.2 PRODUCT PORTFOLIO
19.9.3 RECENT DEVELOPMENTS
19.1 FLUXION BIOSCIENCES INC
19.10.1 COMPANY SNAPSHOT
19.10.2 PRODUCT PORTFOLIO
19.10.3 RECENT DEVELOPMENTS
19.11 ILLUMINA, INC.
19.11.1 COMPANY SNAPSHOT
19.11.2 REVENUE ANALYSIS
19.11.3 SWOT ANALYSIS
19.11.4 PRODUCT PORTFOLIO
19.11.5 RECENT DEVELOPMENT
19.12 JOHNSON & JOHNSON PRIVATE LIMITED
19.12.1 COMPANY SNAPSHOT
19.12.2 REVENUE ANALYSIS
19.12.3 SWOT ANALYSIS
19.12.4 PRODUCT PORTFOLIO
19.12.5 RECENT DEVELOPMENTS
19.13 LABORATORY CORPORATION OF AMERICA HOLDINGS
19.13.1 COMPANY SNAPSHOT
19.13.2 REVENUE ANALYSIS
19.13.3 SWOT ANALYSIS
19.13.4 PRODUCT PORTFOLIO
19.13.5 RECENT DEVELOPMENT
19.14 MDXHEALTH
19.14.1 COMPANY SNAPSHOT
19.14.2 REVENUE ANALYSIS
19.14.3 PRODUCT PORTFOLIO
19.14.4 RECENT DEVELOPMENTS
19.15 MENARINI SILICON BIOSYSTEMS
19.15.1 COMPANY SNAPSHOT
19.15.2 PRODUCT PORTFOLIO
19.15.3 RECENT DEVELOPMENTS
19.16 NATERA, INC.
19.16.1 COMPANY SNAPSHOT
19.16.2 REVENUE ANALYSIS
19.16.3 PRODUCT PORTFOLIO
19.16.4 RECENT DEVELOPMENTS
19.17 NEOGENOMICS LABORATORIES
19.17.1 COMPANY SNAPSHOT
19.17.2 REVENUE ANALYSIS
19.17.3 PRODUCT PORTFOLIO
19.17.4 RECENT DEVELOPMENTS
19.18 ONCOCYTE CORPORATION
19.18.1 COMPANY PROFILE
19.18.2 SERVICE PORTFOLIO
19.18.3 RECENT DEVELOPMENTS
19.19 PATHAI
19.19.1 COMPANY SNAPSHOT
19.19.2 PRODUCT PORTFOLIO
19.19.3 RECENT DEVELOPMENTS
19.2 PREDICINE
19.20.1 COMPANY SNAPSHOT
19.20.2 PRODUCT PORTFOLIO
19.20.3 RECENT DEVELOPMENT
19.21 STRECK
19.21.1 COMPANY SNAPSHOT
19.21.2 PRODUCT PORTFOLIO
19.21.3 RECENT DEVELOPMENTS
19.22 SYSMEX INOSTICS INC.
19.22.1 COMPANY SNAPSHOT
19.22.2 REVENUE ANALYSIS
19.22.3 PRODUCT PORTFOLIO
19.22.4 RECENT DEVELOPMENTS
20 QUESTIONNAIRE
21 RELATED REPORTS
Lista de Tablas
TABLE 1 WAYS IN WHICH LIQUID BIOPSY HAS ADVANCED PRECISION MEDICINE
TABLE 2 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 3 ASIA-PACIFIC CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 4 ASIA-PACIFIC CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 5 ASIA-PACIFIC TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 6 ASIA-PACIFIC COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 7 ASIA-PACIFIC ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 8 ASIA-PACIFIC INSTRUMENTS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 9 ASIA-PACIFIC INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 10 ASIA-PACIFIC SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 11 ASIA-PACIFIC SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 12 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)
TABLE 13 ASIA-PACIFIC CIRCULATING TUMOR CELLS (CTCS) IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 14 ASIA-PACIFIC CIRCULATING CELL-FREE DNA (CFDNA) IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 15 ASIA-PACIFIC CELL-FREE RNA IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 16 ASIA-PACIFIC EXOSOMES IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 17 ASIA-PACIFIC EXTRACELLULAR VESICLES IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 18 ASIA-PACIFIC OTHERS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 19 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 20 ASIA-PACIFIC BLOOD SAMPLE-BASED IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 21 ASIA-PACIFIC URINE SAMPLE-BASED IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 22 ASIA-PACIFIC SALIVA & OTHER TISSUE FLUIDS SAMPLE-BASED IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 23 ASIA-PACIFIC OTHERS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 24 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 25 ASIA-PACIFIC MOLECULAR IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 26 ASIA-PACIFIC MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 27 ASIA-PACIFIC PROTEOMIC IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 28 ASIA-PACIFIC PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 29 ASIA-PACIFIC HISTOLOGY/IMAGING IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 30 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 31 ASIA-PACIFIC CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 32 ASIA-PACIFIC CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 33 ASIA-PACIFIC BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 34 ASIA-PACIFIC NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 35 ASIA-PACIFIC NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 36 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 37 ASIA-PACIFIC ROUTINE SCREENING IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 38 ASIA-PACIFIC THERAPY SELECTION IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 39 ASIA-PACIFIC TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 40 ASIA-PACIFIC TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 41 ASIA-PACIFIC RECURRENCE MONITORING IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 42 ASIA-PACIFIC PATIENT WORK-UP IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 43 ASIA-PACIFIC OTHERS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 44 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 45 ASIA-PACIFIC MULTI-GENE-PARALLEL ANALYSIS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 46 ASIA-PACIFIC SINGLE GENE ANALYSIS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 47 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 48 ASIA-PACIFIC HOSPITALS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 49 ASIA-PACIFIC REFERENCE LABORATORIES IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 50 ASIA-PACIFIC DIAGNOSTICS CENTERS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 51 ASIA-PACIFIC RESEARCH CENTRES AND ACADEMIC INSTITUTES IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 52 ASIA-PACIFIC OTHERS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 53 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 54 ASIA-PACIFIC DIRECT TENDER IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 55 ASIA-PACIFIC THIRD PARTY DISTRIBUTOR IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 56 ASIA-PACIFIC OTHERS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 57 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 58 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 59 ASIA-PACIFIC CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 60 ASIA-PACIFIC CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 61 ASIA-PACIFIC TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 62 ASIA-PACIFIC TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 63 ASIA-PACIFIC COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 64 ASIA-PACIFIC COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 65 ASIA-PACIFIC ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 66 ASIA-PACIFIC INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 67 ASIA-PACIFIC INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 68 ASIA-PACIFIC SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 69 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)
TABLE 70 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 71 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 72 ASIA-PACIFIC MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 73 ASIA-PACIFIC PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 74 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 75 ASIA-PACIFIC CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 76 ASIA-PACIFIC BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 77 ASIA-PACIFIC NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 78 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 79 ASIA-PACIFIC TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 80 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 81 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 82 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 83 JAPAN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 84 JAPAN CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 85 JAPAN CONSUMABLE & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 86 JAPAN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 87 JAPAN TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 88 JAPAN TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 89 JAPAN TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 90 JAPAN COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 91 JAPAN COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 92 JAPAN COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 93 JAPAN ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 94 JAPAN INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 95 JAPAN INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 96 JAPAN INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 97 JAPAN SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 98 JAPAN LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)
TABLE 99 JAPAN LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 100 JAPAN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 101 JAPAN MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 102 JAPAN PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 103 JAPAN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 104 JAPAN CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 105 JAPAN BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 106 JAPAN NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 107 JAPAN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 108 JAPAN TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 109 JAPAN LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 110 JAPAN LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 111 CHINA LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 112 CHINA LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 113 CHINA CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 114 CHINA CONSUMABLE & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 115 CHINA LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 116 CHINA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 117 CHINA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 118 CHINA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 119 CHINA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 120 CHINA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 121 CHINA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 122 CHINA ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 123 CHINA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 124 CHINA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 125 CHINA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 126 CHINA SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 127 CHINA LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)
TABLE 128 CHINA LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 129 CHINA LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 130 CHINA MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 131 CHINA PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 132 CHINA LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 133 CHINA CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 134 CHINA BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 135 CHINA NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 136 CHINA LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 137 CHINA TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 138 CHINA LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 139 CHINA LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 140 CHINA LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 141 SOUTH KOREA LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 142 SOUTH KOREA CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 143 SOUTH KOREA CONSUMABLE & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 144 SOUTH KOREA LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 145 SOUTH KOREA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 146 SOUTH KOREA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 147 SOUTH KOREA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 148 SOUTH KOREA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 149 SOUTH KOREA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 150 SOUTH KOREA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 151 SOUTH KOREA ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 152 SOUTH KOREA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 153 SOUTH KOREA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 154 SOUTH KOREA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 155 SOUTH KOREA SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 156 SOUTH KOREA LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)
TABLE 157 SOUTH KOREA LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 158 SOUTH KOREA LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 159 SOUTH KOREA MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 160 SOUTH KOREA PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 161 SOUTH KOREA LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 162 SOUTH KOREA CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 163 SOUTH KOREA BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 164 SOUTH KOREA NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 165 SOUTH KOREA LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 166 SOUTH KOREA TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 167 SOUTH KOREA LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 168 SOUTH KOREA LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 169 SOUTH KOREA LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 170 INDIA LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 171 INDIA CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 172 INDIA CONSUMABLE & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 173 INDIA LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 174 INDIA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 175 INDIA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 176 INDIA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 177 INDIA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 178 INDIA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 179 INDIA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 180 INDIA ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 181 INDIA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 182 INDIA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 183 INDIA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 184 INDIA SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 185 INDIA LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)
TABLE 186 INDIA LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 187 INDIA LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 188 INDIA MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 189 INDIA PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 190 INDIA LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 191 INDIA CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 192 INDIA BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 193 INDIA NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 194 INDIA LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 195 INDIA TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 196 INDIA LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 197 INDIA LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 198 INDIA LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 199 AUSTRALIA LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 200 AUSTRALIA CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 201 AUSTRALIA CONSUMABLE & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 202 AUSTRALIA LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 203 AUSTRALIA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 204 AUSTRALIA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 205 AUSTRALIA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 206 AUSTRALIA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 207 AUSTRALIA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 208 AUSTRALIA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 209 AUSTRALIA ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 210 AUSTRALIA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 211 AUSTRALIA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 212 AUSTRALIA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 213 AUSTRALIA SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 214 AUSTRALIA LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)
TABLE 215 AUSTRALIA LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 216 AUSTRALIA LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 217 AUSTRALIA MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 218 AUSTRALIA PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 219 AUSTRALIA LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 220 AUSTRALIA CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 221 AUSTRALIA BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 222 AUSTRALIA NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 223 AUSTRALIA LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 224 AUSTRALIA TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 225 AUSTRALIA LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 226 AUSTRALIA LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 227 AUSTRALIA LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 228 SINGAPORE LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 229 SINGAPORE CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 230 SINGAPORE CONSUMABLE & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 231 SINGAPORE LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 232 SINGAPORE TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 233 SINGAPORE TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 234 SINGAPORE TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 235 SINGAPORE COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 236 SINGAPORE COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 237 SINGAPORE COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 238 SINGAPORE ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 239 SINGAPORE INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 240 SINGAPORE INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 241 SINGAPORE INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 242 SINGAPORE SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 243 SINGAPORE LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)
TABLE 244 SINGAPORE LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 245 SINGAPORE LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 246 SINGAPORE MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 247 SINGAPORE PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 248 SINGAPORE LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 249 SINGAPORE CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 250 SINGAPORE BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 251 SINGAPORE NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 252 SINGAPORE LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 253 SINGAPORE TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 254 SINGAPORE LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 255 SINGAPORE LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 256 SINGAPORE LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 257 THAILAND LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 258 THAILAND CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 259 THAILAND CONSUMABLE & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 260 THAILAND LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 261 THAILAND TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 262 THAILAND TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 263 THAILAND TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 264 THAILAND COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 265 THAILAND COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 266 THAILAND COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 267 THAILAND ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 268 THAILAND INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 269 THAILAND INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 270 THAILAND INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 271 THAILAND SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 272 THAILAND LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)
TABLE 273 THAILAND LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 274 THAILAND LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 275 THAILAND MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 276 THAILAND PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 277 THAILAND LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 278 THAILAND CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 279 THAILAND BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 280 THAILAND NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 281 THAILAND LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 282 THAILAND TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 283 THAILAND LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 284 THAILAND LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 285 THAILAND LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 286 MALAYSIA LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 287 MALAYSIA CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 288 MALAYSIA CONSUMABLE & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 289 MALAYSIA LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 290 MALAYSIA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 291 MALAYSIA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 292 MALAYSIA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 293 MALAYSIA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 294 MALAYSIA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 295 MALAYSIA ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 296 MALAYSIA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 297 MALAYSIA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 298 MALAYSIA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 299 MALAYSIA SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 300 MALAYSIA LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)
TABLE 301 MALAYSIA LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 302 MALAYSIA LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 303 MALAYSIA MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 304 MALAYSIA PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 305 MALAYSIA LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 306 MALAYSIA CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 307 MALAYSIA BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 308 MALAYSIA NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 309 MALAYSIA LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 310 MALAYSIA TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 311 MALAYSIA LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 312 MALAYSIA LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 313 MALAYSIA LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 314 INDONESIA LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 315 INDONESIA CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 316 INDONESIA CONSUMABLE & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 317 INDONESIA LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 318 INDONESIA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 319 INDONESIA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 320 INDONESIA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 321 INDONESIA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 322 INDONESIA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 323 INDONESIA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 324 INDONESIA ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 325 INDONESIA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 326 INDONESIA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 327 INDONESIA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 328 INDONESIA SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 329 INDONESIA LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)
TABLE 330 INDONESIA LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 331 INDONESIA LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 332 INDONESIA MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 333 INDONESIA PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 334 INDONESIA LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 335 INDONESIA CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 336 INDONESIA BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 337 INDONESIA NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 338 INDONESIA LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 339 INDONESIA TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 340 INDONESIA LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 341 INDONESIA LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 342 INDONESIA LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 343 PHILIPPINES LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 344 PHILIPPINES CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 345 PHILIPPINES CONSUMABLE & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 346 PHILIPPINES LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 347 PHILIPPINES TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 348 PHILIPPINES TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 349 PHILIPPINES TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 350 PHILIPPINES COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 351 PHILIPPINES COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 352 PHILIPPINES COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 353 PHILIPPINES ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 354 PHILIPPINES INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 355 PHILIPPINES INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 356 PHILIPPINES INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 357 PHILIPPINES SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 358 PHILIPPINES LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)
TABLE 359 PHILIPPINES LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 360 PHILIPPINES LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 361 PHILIPPINES MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 362 PHILIPPINES PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 363 PHILIPPINES LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 364 PHILIPPINES CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 365 PHILIPPINES BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 366 PHILIPPINES NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 367 PHILIPPINES LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 368 PHILIPPINES TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 369 PHILIPPINES LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 370 PHILIPPINES LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 371 PHILIPPINES LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 372 REST OF ASIA-PACIFIC LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
Lista de figuras
FIGURE 1 ASIA-PACIFIC LIQUID BIOPSY MARKET: SEGMENTATION
FIGURE 2 ASIA-PACIFIC LIQUID BIOPSY MARKET: DATA TRIANGULATION
FIGURE 3 ASIA-PACIFIC LIQUID BIOPSY MARKET: DROC ANALYSIS
FIGURE 4 ASIA-PACIFIC LIQUID BIOPSY MARKET: ASIA-PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA-PACIFIC LIQUID BIOPSY MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA-PACIFIC LIQUID BIOPSY MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA-PACIFIC LIQUID BIOPSY MARKET: DBMR MARKET POSITION GRID
FIGURE 8 ASIA-PACIFIC LIQUID BIOPSY MARKET: MARKET TESTING TYPE COVERAGE GRID
FIGURE 9 ASIA-PACIFIC LIQUID BIOPSY MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA-PACIFIC LIQUID BIOPSY MARKET: SEGMENTATION
FIGURE 11 THE GROWING DEMAND FOR NON-INVASIVE CANCER DIAGNOSTICS IS EXPECTED TO DRIVE THE ASIA-PACIFIC LIQUID BIOPSY MARKET GROWTH IN THE FORECAST PERIOD
FIGURE 12 CONSUMABLES & ACCESSORIES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC LIQUID BIOPSY MARKET IN 2023 & 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ASIA-PACIFIC LIQUID BIOPSY MARKET
FIGURE 14 ADVANTAGES OF LIQUID BIOPSY OVER TRADITIONAL BIOPSY
FIGURE 15 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY PRODUCT, 2022
FIGURE 16 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY PRODUCT, 2023-2030 (USD MILLION)
FIGURE 17 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY PRODUCT, CAGR (2023-2030)
FIGURE 18 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 19 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY BIOMAKER TYPE, 2022
FIGURE 20 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY BIOMAKER TYPE, 2023-2030 (USD MILLION)
FIGURE 21 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY BIOMAKER TYPE, CAGR (2023-2030)
FIGURE 22 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY BIOMAKER TYPE, LIFELINE CURVE
FIGURE 23 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY SAMPLE TYPE, 2022
FIGURE 24 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY SAMPLE TYPE, 2023-2030 (USD MILLION)
FIGURE 25 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY SAMPLE TYPE, CAGR (2023-2030)
FIGURE 26 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY SAMPLE TYPE, LIFELINE CURVE
FIGURE 27 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY ANALYTICAL TYPE, 2022
FIGURE 28 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY ANALYTICAL TYPE, 2023-2030 (USD MILLION)
FIGURE 29 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY ANALYTICAL TYPE, CAGR (2023-2030)
FIGURE 30 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY ANALYTICAL TYPE, LIFELINE CURVE
FIGURE 31 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY APPLICATION TYPE, 2022
FIGURE 32 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY APPLICATION TYPE, 2023-2030 (USD MILLION)
FIGURE 33 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY APPLICATION TYPE, CAGR (2023-2030)
FIGURE 34 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY APPLICATION TYPE, LIFELINE CURVE
FIGURE 35 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY CLINICAL APPLICATION, 2022
FIGURE 36 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
FIGURE 37 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY CLINICAL APPLICATION, CAGR (2023-2030)
FIGURE 38 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY CLINICAL APPLICATION, LIFELINE CURVE
FIGURE 39 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY TECHNOLOGY, 2022
FIGURE 40 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY TECHNOLOGY, 2023-2030 (USD MILLION)
FIGURE 41 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY TECHNOLOGY, CAGR (2023-2030)
FIGURE 42 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 43 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY END USER, 2022
FIGURE 44 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 45 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY END USER, CAGR (2023-2030)
FIGURE 46 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY END USER, LIFELINE CURVE
FIGURE 47 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 48 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 49 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 50 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 51 ASIA-PACIFIC LIQUID BIOPSY MARKET: SNAPSHOT (2022)
FIGURE 52 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY COUNTRY (2022)
FIGURE 53 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY COUNTRY (2023 & 2030)
FIGURE 54 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY COUNTRY (2022 & 2030)
FIGURE 55 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY PRODUCT (2023-2030)
FIGURE 56 ASIA-PACIFIC LIQUID BIOPSY MARKET: COMPANY SHARE 2022 (%)
Metodología de investigación
La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.
La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.
Personalización disponible
Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.
